Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Certolizumab in Women With Unexplained Recurrent Implantation Failure: a Double-blind Randomized Controlled Trial

NCT05930613 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05930613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05930613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Certolizumab in Women With Unexplained Recurrent Implantation Failure: a Double-blind Randomized Controlled Trial
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 3
Overall status
Recruiting
Start date
November 30, 2023
Completion date
April 30, 2029
Enrollment
161 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent unexplained implantation failure